Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

High preoperative blood levels of HE4 predicts poor prognosis in patients with ovarian cancer.

Kalapotharakos G, Asciutto C, Henic E, Casslén B, Borgfeldt C.

J Ovarian Res. 2012 Aug 21;5(1):20. doi: 10.1186/1757-2215-5-20.

2.

Cleaved forms of the urokinase plasminogen activator receptor in plasma have diagnostic potential and predict postoperative survival in patients with ovarian cancer.

Henic E, Borgfeldt C, Christensen IJ, Casslén B, Høyer-Hansen G.

Clin Cancer Res. 2008 Sep 15;14(18):5785-93. doi: 10.1158/1078-0432.CCR-08-0096.

3.
4.

Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: correlation with pathological outcome.

Sandri MT, Bottari F, Franchi D, Boveri S, Candiani M, Ronzoni S, Peiretti M, Radice D, Passerini R, Sideri M.

Gynecol Oncol. 2013 Feb;128(2):233-8. doi: 10.1016/j.ygyno.2012.11.026. Epub 2012 Nov 28.

PMID:
23200911
5.

[Diagnostic value of combining detection of human epididymis protein 4 and CA125 in patients with malignant ovarian carcinoma].

Wang MJ, Qi J, Wang H, Li XX, Wei BJ, Fu C, Gao J, Han BB.

Zhonghua Zhong Liu Za Zhi. 2011 Jul;33(7):540-3. Chinese.

PMID:
22093635
6.

Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.

Karlsen MA, Sandhu N, Høgdall C, Christensen IJ, Nedergaard L, Lundvall L, Engelholm SA, Pedersen AT, Hartwell D, Lydolph M, Laursen IA, Høgdall EV.

Gynecol Oncol. 2012 Nov;127(2):379-83. doi: 10.1016/j.ygyno.2012.07.106. Epub 2012 Jul 24.

PMID:
22835718
7.

Preoperative HE4, CA125 and ROMA in the differential diagnosis of benign and malignant adnexal masses.

Terlikowska KM, Dobrzycka B, Witkowska AM, Mackowiak-Matejczyk B, Sledziewski TK, Kinalski M, Terlikowski SJ.

J Ovarian Res. 2016 Jul 19;9(1):43. doi: 10.1186/s13048-016-0254-7.

8.

Symptoms, CA125 and HE4 for the preoperative prediction of ovarian malignancy in Brazilian women with ovarian masses.

Pitta Dda R, Sarian LO, Barreta A, Campos EA, Andrade LL, Fachini AM, Campbell LM, Derchain S.

BMC Cancer. 2013 Sep 18;13:423. doi: 10.1186/1471-2407-13-423.

9.

Does risk for ovarian malignancy algorithm excel human epididymis protein 4 and CA125 in predicting epithelial ovarian cancer: a meta-analysis.

Li F, Tie R, Chang K, Wang F, Deng S, Lu W, Yu L, Chen M.

BMC Cancer. 2012 Jun 19;12:258. doi: 10.1186/1471-2407-12-258.

10.

HE4 can help discriminate women with malignant ovarian 
tumors only if CA125 levels are elevated.

Pitta Dda R, Sarian LO, Campos EA, Andrade LL, Sallum LF, Bragança JF, Campos Cde M, Derchain S.

Int J Biol Markers. 2013 Oct-Dec;28(4):e377-86.

PMID:
23828407
11.

HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm.

Van Gorp T, Cadron I, Despierre E, Daemen A, Leunen K, Amant F, Timmerman D, De Moor B, Vergote I.

Br J Cancer. 2011 Mar 1;104(5):863-70. doi: 10.1038/sj.bjc.6606092. Epub 2011 Feb 8.

12.

HE4 and ROMA index in Czech postmenopausal women.

Novotny Z, Presl J, Kucera R, Topolcan O, Vrzalova J, Fuchsova R, Betincova L, Rokyta Z.

Anticancer Res. 2012 Sep;32(9):4137-40.

PMID:
22993374
13.

The utility of human epididymal protein 4, cancer antigen 125, and risk for malignancy algorithm in ovarian cancer and endometriosis.

Kadija S, Stefanovic A, Jeremic K, Radojevic MM, Nikolic L, Markovic I, Atanackovic J.

Int J Gynecol Cancer. 2012 Feb;22(2):238-44. doi: 10.1097/IGC.0b013e318234f852.

PMID:
22214964
14.

Prognostic impact of prechemotherapy serum levels of HER2, CA125, and HE4 in ovarian cancer patients.

Steffensen KD, Waldstrøm M, Brandslund I, Jakobsen A.

Int J Gynecol Cancer. 2011 Aug;21(6):1040-7. doi: 10.1097/IGC.0b013e31821e052e.

PMID:
21738039
15.

Prognostic value of serum HE4 levels and risk of ovarian malignancy algorithm scores at the time of ovarian cancer diagnosis.

Kaijser J, Van Belle V, Van Gorp T, Sayasneh A, Vergote I, Bourne T, Van Calster B, Timmerman D.

Int J Gynecol Cancer. 2014 Sep;24(7):1173-80. doi: 10.1097/IGC.0000000000000181.

PMID:
24987915
16.

A comparison of CA125, HE4, risk ovarian malignancy algorithm (ROMA), and risk malignancy index (RMI) for the classification of ovarian masses.

Anton C, Carvalho FM, Oliveira EI, Maciel GA, Baracat EC, Carvalho JP.

Clinics (Sao Paulo). 2012;67(5):437-41.

17.

The use of HE4 in the prediction of ovarian cancer in Asian women with a pelvic mass.

Chan KK, Chen CA, Nam JH, Ochiai K, Wilailak S, Choon AT, Sabaratnam S, Hebbar S, Sickan J, Schodin BA, Sumpaico WW.

Gynecol Oncol. 2013 Feb;128(2):239-44. doi: 10.1016/j.ygyno.2012.09.034. Epub 2012 Oct 10.

PMID:
23063998
18.

Serum HE4 as a useful biomarker in discriminating ovarian cancer from benign pelvic disease.

Zheng H, Gao Y.

Int J Gynecol Cancer. 2012 Jul;22(6):1000-5. doi: 10.1097/IGC.0b013e318249bee7.

PMID:
22426406
19.

Diagnostic Accuracy And Cost-Effectiveness Of Different Strategies To Triage Adnexal Masses: A Prospective Study.

Piovano E, Cavallero C, Fuso L, Viora E, Ferrero A, Gregori G, Grillo C, Macchi C, Mengozzi G, Mitidieri M, Pagano E, Zola P.

Ultrasound Obstet Gynecol. 2016 Oct 5. doi: 10.1002/uog.17320. [Epub ahead of print]

PMID:
27706929
20.

Preoperative HE4 and ROMA values do not improve the CA125 diagnostic value for borderline tumors of the ovary (BOT) - a study of the TOC Consortium.

Braicu EI, Van Gorp T, Nassir M, Richter R, Chekerov R, Gasimli K, Timmerman D, Vergote I, Sehouli J.

J Ovarian Res. 2014 May 7;7:49. doi: 10.1186/1757-2215-7-49. eCollection 2014.

Supplemental Content

Support Center